Gastroesophageal reflux disease and Barrett's Esophagus seem like obvious-and enormous-potential markets for interventional devices, but so far such devices have disappointed. In GERD, product malfunctions and recalls have underscored safety issues, while efficacy concerns and reimbursement delays have conspired to keep the enormous opportunity that GERD represents tantalizingly out of reach for many of the first-generation companies that were launched to tap into this market. Now, a small group of companies with hopes of a better approach are betting they've found the way to harness this most promising of device markets.
By Mary Stuart
In the western world, many a spouse experiences the inconvenience of having to sleep with someone with gastroesophageal reflux disease...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
A Johns Hopkins University study found publicly traded companies are responsible for 90% of recalled AI-powered medical devices. The study attributes this link to lower clinical validation, especially among smaller companies, and advocates for increased clinical trials to enhance device safety.
The value proposition of surgical robots is quickly changing. Gone is the focus on benefit to patients; instead cost, operative efficiency and surgeon longevity are the new focal points, making deciphering M&A value much more difficult.
Medicare’s device coverage process is “a system in crisis,” consultant Bruce Quinn warned at the NextGen Dx Summit. He criticized bloated NCDs, stalled advisory committees, and years-long delays, urging CMS to streamline LCDs and adopt a six-month “fast-track” model to speed innovation access.
